PC-mAb is under clinical development by Athera Biotechnologies and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PC-mAb’s likelihood of approval (LoA) and phase transition for Myocardial Infarction took place on 27 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PC-mAb Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PC-mAb overview

PC-mAb is under development for the prevention of myocardial infarction, acute coronary syndrome, arterial inflammation associated with atherosclerosis, peripheral arterial disease and for  prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis. The therapeutic candidate is a monoclonal antibody which is based on phosphorylcholine(PC). Phosphorylcholine is a zwitterionic phospholipid found on the outer surface of red blood cell membranes. It is administered through intravenous route.

Athera Biotechnologies overview

Athera Biotechnologies (Athera) is a clinical stage biopharmaceutical company that focuses on the development of anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease. The company develops a proprietary clinical development stage program, PC-mAb, a human monoclonal antibody used to treat vascular disease, peripheral artery disease, heart failure, arteriovenous dysfunction in dialysis patients, and arterial inflammation. It also develops a proprietary companion diagnostic CVDefine kit to identify patients with low levels of natural anti-PC antibodies. Athera offers clinical development and clinical trials services. The company partners with pharmaceutical, biotechnology and diagnostics companies. Athera is headquartered in Stockholm, Sweden.

Quick View PC-mAb LOA Data

Report Segments
  • Innovator
Drug Name
  • PC-mAb
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.